RGNX News
Archived Headlines
- US IPO Weekly Recap: Health care goes three for three as IPOs trade up 30% 09/18/15
- REGENXBIO prices upsized IPO at $22, above the original range 09/17/15
- Gene therapy biotech REGENXBIO increases proposed IPO price to $22 09/16/15
- Week ahead: 3 health care IPOs set to price during the week of September 14 09/14/15
- REGENXBIO sets terms for $100 million IPO 09/08/15
See more
Looking to fight Leukemia: Syros Pharmaceuticals files for a $69 million IPO
Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, filed on Friday with the SEC to raise up to $69 million in an initial public offering. The Cambridge, MA-based company was founded in 2011. It plans to list on...read more
Making rare diseases rarer: Gene therapy biotech AveXis sets terms for $85 million IPO
AveXis, an early-stage biotech developing gene therapies for rare neurological diseases, announced terms for its IPO on Monday. The Bannockburn, IL-based company plans to raise $85 million by offering 4.25 million shares at a price range of $19 to $21....read more
US IPO Weekly Recap: The only IPO delays as the market falls for the second straight week
A bad start to the year only got worse this week as the S&P 500 fell another 2%. For the first time since October, the ninety-day returns swung negative to -0.6%. Just two weeks ago, that number stood at 17%. The VIX is up 48% year-to-date, closing...read more
Parkinson's biotech Voyager Therapeutics sets terms for $75 million IPO
Voyager Therapeutics, a gene therapy biotech targeting Parkinson's disease and other CNS disorders, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to...read more